Recent findings suggest that post-COVID chronic cough may be driven by neurological factors, not just respiratory issues.

whose P2X3 drug BLU-5937 is now closest behind gefapixant in clinical development. BLU-5937 hit the mark in the mid-stage SOOTHE trial in refractory chronic cough towards the end of last year ...

It has pointed to a lower tendency to cause taste disturbances (dysgeusia) than other compounds ... a P2X3 drug called sivopixant (S-600918) in mid-stage clinical testing for chronic cough ...